Twist Bioscience Corporation $TWST Position Trimmed by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC decreased its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 47.6% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 22,539 shares of the company’s stock after selling 20,501 shares during the quarter. Conestoga Capital Advisors LLC’s holdings in Twist Bioscience were worth $4,355,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of TWST. Integrity Alliance LLC. purchased a new position in Twist Bioscience during the 3rd quarter worth $430,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Twist Bioscience in the third quarter valued at about $5,712,000. ProShare Advisors LLC boosted its holdings in shares of Twist Bioscience by 4.3% in the third quarter. ProShare Advisors LLC now owns 10,615 shares of the company’s stock valued at $2,051,000 after acquiring an additional 441 shares in the last quarter. Vise Technologies Inc. purchased a new stake in shares of Twist Bioscience in the third quarter valued at about $372,000. Finally, State of Wyoming increased its stake in shares of Twist Bioscience by 25.3% during the third quarter. State of Wyoming now owns 2,242 shares of the company’s stock worth $433,000 after acquiring an additional 452 shares during the period.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Jefferies Financial Group began coverage on shares of Twist Bioscience in a research report on Thursday, October 8th. They issued a “hold” rating and a $150.00 price objective for the company. Guggenheim boosted their target price on Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Leerink Partners increased their target price on Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. UBS Group began coverage on Twist Bioscience in a report on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price target for the company. Finally, BWS Financial reaffirmed a “sell” rating and set a $45.00 price objective on shares of Twist Bioscience in a report on Friday, September 18th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $153.00.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $142.58 on Thursday. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $219.71. The company has a market capitalization of $8.94 billion, a P/E ratio of -64.22 and a beta of 2.25. The business has a 50 day moving average price of $152.59 and a 200 day moving average price of $90.28. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38.

Twist Bioscience (NASDAQ:TWST) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The firm had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.33 earnings per share. Sell-side analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insider Activity

In other news, insider Dennis Cho sold 9,514 shares of the stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,797,004.32. Following the transaction, the insider directly owned 63,789 shares in the company, valued at $12,048,466.32. This represents a 12.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of Twist Bioscience stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the completion of the transaction, the senior vice president owned 106,632 shares in the company, valued at approximately $20,140,652.16. This trade represents a 8.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 601,920 shares of company stock worth $93,768,202 in the last quarter. 3.08% of the stock is currently owned by corporate insiders.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.